Health Technology Innovations

Executive Summary

Health Technology Innovations (HTI) is a New York-based biotechnology company that accelerates structure-based drug discovery through cryo-electron microscopy (cryo-EM) services and proprietary AI/ML software. Founded in 2018, HTI offers end-to-end structural analysis services and its CryoDiscovery™ and CryoFAST™ platforms, which automate image processing and data collection, making high-resolution structural biology faster, more affordable, and scalable. The company targets pharmaceutical researchers seeking to understand protein structures for drug design. With the growing demand for cryo-EM in drug discovery, HTI is well-positioned to capture market share by combining service revenue with software licensing. Its focus on automation and AI addresses key bottlenecks in cryo-EM, such as time-intensive data analysis and low throughput. However, as a private company with limited disclosed financials, HTI faces competition from established players like Thermo Fisher and newer AI-driven startups. The company's success hinges on securing major pharma partnerships, advancing its software capabilities, and raising capital to scale operations.

Upcoming Catalysts (preview)

• Q3 2026Major Pharmaceutical Partnership60% success
• Q4 2026Launch of CryoFAST v2.0 Software70% success
• Q2 2026Series A Funding Round Closure65% success